论文部分内容阅读
目的 探讨长春瑞宾 (NVB)联合顺铂 (PDD)治疗非小细胞肺癌患者影响疗效、预后的因素。方法 分别选择临床病理因素 ,应用Logistic回归及Cox比例风险模型对影响疗效、预后的因素进行分析。结果 全组总有效率 (RR)为 30 .2 % (6 2 / 2 0 5 ) ,其中初治为 32 .0 % (4 8/ 1 5 0 ) ,复治为 2 6 .5 % (1 4 / 5 5 ) ,中位生存期 8.3个月 ,1年生存率为 37.81 % ,2年生存率为 1 5 .4 4 % ,3年生存率为 5 .39%。多因素分析显示 ,女性、肺鳞癌及治疗前一般状况较好者有较好的疗效 (P <0 .0 5 ) ;治疗前体重丢失情况与完成治疗的周期数 (P <0 .0 0 0 5 )为影响预后因素 ,肺腺癌患者在本组获得较长生存期。结论 NVB联合顺铂是治疗非小细胞肺癌较好的方案 ,影响疗效重要因素为性别、病理类型及一般状况。本组影响预后因素为治疗前体重丢失情况、完成治疗的周期数 ,肺腺癌在本组获得较长生存期。
Objective To investigate the effect of vinorelbine (NVB) combined with cisplatin (PDD) on non-small cell lung cancer (NSCLC) patients. Methods Clinicopathological factors were selected, and Logistic regression and Cox proportional hazards model were used to analyze the factors influencing curative effect and prognosis. Results The total effective rate (RR) of the whole group was 30.2% (62/250), of which the initial treatment was 32.0% (48/150) and the retreatment was 26.5% (1) The median survival time was 8.3 months. The 1-year survival rate was 37.81%, the 2-year survival rate was 15.44%, and the 3-year survival rate was 5.39%. Multivariate analysis showed that women, lung squamous cell carcinoma and patients with better general condition before treatment had better curative effect (P <0.05); the weight loss before treatment and the number of cycles completed (P <0.05) 0 5) To influence prognosis, patients with lung adenocarcinoma had longer survival in this group. Conclusions NVB combined with cisplatin is a good treatment for non-small cell lung cancer. The important factors influencing efficacy are gender, pathological type and general condition. The prognosis of this group of factors for the loss of weight before treatment, the number of cycles to complete treatment, lung adenocarcinoma in this group to obtain longer survival.